Form 4: Voyager Therapeutics CEO Alfred Sandrock Reports Stock Transactions
SEC Form 4
CEO Alfred Sandrock of Voyager Therapeutics reports the sale of shares to cover tax obligations and the acquisition of restricted stock units and stock options.
Summary
- Alfred Sandrock, CEO of Voyager Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On February 20, 2025, Sandrock sold 11,702 shares of common stock at an average price of $4.24 to cover tax obligations related to vesting restricted stock units.
- On February 21, 2025, Sandrock acquired 145,000 shares of common stock through restricted stock units (RSUs) and was granted an option to buy 290,000 shares.
- Following these transactions, Sandrock beneficially owns 441,816 shares of common stock and options to purchase 290,000 shares.
- The RSUs vest over three years, and the stock options vest over four years, both contingent upon continued service.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of unusual activity or concerns.
Positives
- The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedules for the RSUs and stock options incentivize continued service and commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be an indicator of management's confidence in the company's future prospects. The vesting schedules are typical for executive compensation packages in the biotech industry.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include a mix of salary, stock options, and restricted stock units.
- Vesting schedules of three to four years are common to incentivize long-term commitment.
- Comparing Voyager Therapeutics' executive compensation structure to companies like BioMarin, Sarepta Therapeutics, or Alnylam Pharmaceuticals would provide a more detailed benchmark.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the sale of shares to cover tax obligations and the issuance of new equity as part of the CEO's compensation.
- Employees are indirectly impacted as the CEO's incentives are aligned with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 02/17/2025 | Vesting of restricted stock units triggering tax withholding obligations. |
| 02/20/2025 | Sale of 11,702 shares of common stock to cover tax obligations. |
| 02/21/2025 | Grant date of 145,000 restricted stock units and stock options for 290,000 shares. |
| 02/24/2025 | Date of Form 4 filing. |
| 02/21/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.